Medivir AB (MVIRb.ST)

MVIRb.ST on Stockholm Stock Exchange

119.25SEK
22 Aug 2014
Price Change (% chg)

-7.25kr (-5.73%)
Prev Close
126.50kr
Open
124.00kr
Day's High
124.00kr
Day's Low
118.50kr
Volume
483,059
Avg. Vol
225,937
52-wk High
151.00kr
52-wk Low
76.25kr

MVIRb.ST

Chart for MVIRb.ST

About

Medivir AB is a Sweden-based pharmaceutical company engaged in the research, development and sale of drugs against widespread diseases, with protease and polymerase as its target enzymes. The Company’s research focuses on developing small molecule pharmaceuticals, primarily against infectious diseases caused by viruses. The... (more)

Overall

Beta: 1.51
Market Cap (Mil.): kr3,863.25
Shares Outstanding (Mil.): 30.60
Dividend: --
Yield (%): --

Financials

  MVIRb.ST Industry Sector
P/E (TTM): 17.35 18.12 33.79
EPS (TTM): 7.27 -- --
ROI: 21.15 9.50 49.81
ROE: 21.88 10.93 58.14
Search Stocks

BRIEF-Medivir swings to Q2 profit after tax

Aug 21 - Medivir : * Q2 - net turnover totalled SEK 564.0 million (40.7) * Q2 profit after tax was SEK 327.8 million (-63.7) Link to press release: http://mb.cision.com/Main/652/9631260/277089.pdf

21 Aug 2014

BRIEF-Medivir licenses Respiratory Syncytial Virus drug program from Boehringer Ingelheim

Aug 4 - Medivir : * Licenses respiratory syncytial virus drug program from boehringer ingelheim * Medivir today announces that it has entered a license agreement with Boehringer Ingelheim International GmbH for exclusive, global rights to a drug program for the treatment and prevention of Respiratory Syncytial Virus (RSV) infection. * Under the terms of the agreement Medivir receives an exclusive, global license to research, develop, manufacture and commercialise RSV drugs resulting

04 Aug 2014

BRIEF-Medivir says positive results from combination study with simeprevir

July 28 - Medivir : * Phase II cosmos study results published in the lancet on world hepatitis day * Says 92 percent of genotype 1 chronic hepatitis c virus adult patients

28 Jul 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters StreetEvents
$75.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks